124 related articles for article (PubMed ID: 32499312)
41. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer.
Boyne DJ; Cheung WY; Hilsden RJ; Sajobi TT; Batra A; Friedenreich CM; Brenner DR
JAMA Netw Open; 2021 Mar; 4(3):e213587. PubMed ID: 33783516
[TBL] [Abstract][Full Text] [Related]
42. Perineural Invasion Is a Prognostic but not a Predictive Factor in Nonmetastatic Colon Cancer.
Leijssen LGJ; Dinaux AM; Taylor MS; Deshpande V; Kunitake H; Bordeianou LG; Berger DL
Dis Colon Rectum; 2019 Oct; 62(10):1212-1221. PubMed ID: 31490830
[TBL] [Abstract][Full Text] [Related]
43. Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population.
Osterman E; Glimelius B
Dis Colon Rectum; 2018 Sep; 61(9):1016-1025. PubMed ID: 30086050
[TBL] [Abstract][Full Text] [Related]
44. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
45. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial.
Dahdaleh FS; Sherman SK; Poli EC; Vigneswaran J; Polite BN; Sharma MR; Catenacci DV; Maron SB; Turaga KK
Surgery; 2018 Dec; 164(6):1223-1229. PubMed ID: 30297240
[TBL] [Abstract][Full Text] [Related]
46. Predictors of recurrence free survival for patients with stage II and III colon cancer.
Tsikitis VL; Larson DW; Huebner M; Lohse CM; Thompson PA
BMC Cancer; 2014 May; 14():336. PubMed ID: 24886281
[TBL] [Abstract][Full Text] [Related]
47. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
48. Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival.
Thirunavukarasu P; Talati C; Munjal S; Attwood K; Edge SB; Francescutti V
JAMA Surg; 2015 Aug; 150(8):747-755. PubMed ID: 26083632
[TBL] [Abstract][Full Text] [Related]
49. Controversial Issues Regarding Obligatory Adjuvant Chemotherapy for Stage IIIA Colon Cancer.
Kim CW; Kim TW; Lee JL; Park IJ; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2020 Dec; 19(4):e157-e163. PubMed ID: 32896486
[TBL] [Abstract][Full Text] [Related]
50. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
51. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
52. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Pavelitz T; Renfro L; Foster NR; Caracol A; Welsch P; Lao VV; Grady WB; Niedzwiecki D; Saltz LB; Bertagnolli MM; Goldberg RM; Rabinovitch PS; Emond M; Monnat RJ; Maizels N
PLoS One; 2014; 9(10):e108483. PubMed ID: 25310185
[TBL] [Abstract][Full Text] [Related]
53. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
54. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort.
Hines RB; Bimali M; Johnson AM; Bayakly AR; Collins TC
Cancer Epidemiol; 2016 Oct; 44():77-83. PubMed ID: 27513721
[TBL] [Abstract][Full Text] [Related]
55. Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer.
Hanna N; Bikov KA; McNally D; Onwudiwe NC; Dalal M; Mullins CD
Oncologist; 2012; 17(9):1191-7. PubMed ID: 22767876
[TBL] [Abstract][Full Text] [Related]
56. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
57. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
[TBL] [Abstract][Full Text] [Related]
58. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
59. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
[TBL] [Abstract][Full Text] [Related]
60. Outcome of colon cancer initially presenting as colon perforation and obstruction.
Chen TM; Huang YT; Wang GC
World J Surg Oncol; 2017 Aug; 15(1):164. PubMed ID: 28841901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
